Lineage Cell Therapeutics, Inc. (LCTX) Free cash flow 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$19.4MFY2025 · since FY2016: -$44.6M → -$19.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$19.4M | +17.8% |
| FY2024 | -$23.7M | +19.1% |
| FY2023 | -$29.2M | -4626.3% |
| FY2022 | $646,000 | +102.7% |
| FY2021 | -$23.9M | -20.6% |
| FY2020 | -$19.8M | +38.8% |
| FY2019 | -$32.4M | -3.0% |
| FY2018 | -$31.4M | +1.3% |
| FY2017 | -$31.8M | +28.6% |
| FY2016 | -$44.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX RevenueLCTX Net incomeLCTX Net marginLCTX Gross profitLCTX Gross marginLCTX Operating incomeLCTX Operating marginLCTX Operating cash flowLCTX Capital expendituresLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →